NCT02406183View on ClinicalTrials.gov

Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
MelanomaEffects of ImmunotherapyAdverse Effect of Radiation Therapy
Interventions
RADIATION

Stereotactic body radiotherapy (SBRT)

The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43

DRUG

Ipilimumab

Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64

Trial Locations (1)

9000

Dept. of Radiotherapy, Ghent University Hospital, Ghent

All Listed Sponsors
lead

Radiotherapie

OTHER

NCT02406183 - Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma | Biotech Hunter | Biotech Hunter